Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 9:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 843 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo equivalent Clear all

Conditions: Ischemia Reperfusion Injury
Interventions: recombinant P-selectin glycoprotein ligand Ig fusion protein, Viaspan® and saline; Drug
Lead sponsor: Y's Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Overweight and Obesity
Interventions: Setmelanotide, Placebo; Drug
Lead sponsor: Rhythm Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 2
States / cities: Dallas, Texas • Madison, Wisconsin

Conditions: Psychological Trauma
Interventions: Transcranial Magnetic Stimulation (TMS), TMS Sham; Device · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: HIV Infections, Staphylococcal Infections
Interventions: Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%, Placebo; Drug
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 4
States / cities: San Diego, California • Bethesda, Maryland • San Antonio, Texas + 1 more

Conditions: Hallux Valgus Deformity
Interventions: CA-008, Placebo; Drug
Lead sponsor: Concentric Analgesics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Chronic Kidney Diseases
Interventions: Bardoxolone methyl oral capsule, Placebo oral capsule; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 12
States / cities: La Mesa, California • Arvada, Colorado • Denver, Colorado + 9 more

Conditions: Acute Ischemic Stroke
Interventions: Redasemtide, Placebo; Biological · Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years and older
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 17
States / cities: Tucson, Arizona • Sarasota, Florida • Augusta, Georgia + 14 more

Conditions: Lymphoma,Non-Hodgkin
Interventions: Copanlisib (Aliqopa, BAY80-6946), Placebo, Rituximab; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 16
States / cities: West Covina, California • Ashland, Kentucky • Louisville, Kentucky + 10 more

Conditions: Stroke, Secondary Prevention
Interventions: optional ASA as comedication, placebo to ASA, placebo to optional ASA as comedication, placebo to dabigatran etexilate, ASA 100 mg, dabigatran etexilate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 150 Years
Enrollment: 5,390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 110
States / cities: Phoenix, Arizona • Beverly Hills, California • El Cajon, California + 94 more

Conditions: Androgenetic Alopecia, Hair Loss, Thinning Hair, Balding
Interventions: Genix, Sham; Device
Lead sponsor: Kiierr International, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Mendham, New Jersey

Conditions: Irritable Aggression
Interventions: Divalproex; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 7 Years to 11 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2004
U.S. locations: 1
States / cities: New York, New York

Conditions: Treatment Resistant Depression
Interventions: MK-1942, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 45
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Bellflower, California + 40 more

Conditions: Post Operative Nausea and Vomiting, Rescue Emetic Therapy
Interventions: Metaclopramide, Ondansetron, diphenhydramine, Saline; Drug
Lead sponsor: Franklyn Cladis; Other
Eligibility: 3 Years to 18 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Moderate to Severe Glabellar Frown Lines
Interventions: IncobotulinumtoxinA (Xeomin) (20 Units), Placebo; Drug
Lead sponsor: Merz Pharmaceuticals GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 5
States / cities: Los Angeles, California • Meatrie, Louisiana • Chestnut Hill, Massachusetts + 2 more

Conditions: Metastatic Hormone-sensitive Prostate Cancer
Interventions: BAY1841788 / darolutamide (ODM-201), Standard ADT (androgen deprivation therapy), Docetaxel, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 58
States / cities: Chandler, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more

Conditions: Pathological Gambling
Interventions: Topiramate, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 70 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Schizophrenia
Interventions: PP6M, PP3M 350 mg eq., PP3M 525 mg eq., PP1M, Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 841 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 25
States / cities: Rogers, Arkansas • Anaheim, California • Costa Mesa, California + 21 more

Conditions: Prurigo Nodularis
Interventions: Nemolizumab 30 mg, Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 38
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 32 more

Conditions: Rheumatoid Arthritis
Interventions: pioglitazone, Sublingual nitroglycerine; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years to 100 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Benign Prostatic Hyperplasia
Interventions: Tranexamic Acid (IV), Placebo; Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 45 Years and older · Male only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Sarcoidosis
Interventions: Antibiotic Regimen, Placebo Regimen; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: TTR Cardiomyopathy
Interventions: Period 1, Period 2, Period 3; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Placebo, Tozorakimab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 130 Years
Enrollment: 1,454 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 57
States / cities: Birmingham, Alabama • Decatur, Alabama • Sheffield, Alabama + 51 more

Conditions: Disorder of Urinary Stent, Ureteral Spasm, Ureteropelvic Junction Obstruction, Urolithiasis
Interventions: Ibuprofen, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 4 Years to 17 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Search by objective public record fields.

YSPSL for Prevention of Ischemic Reperfusion Injury in Patients Undergoing Cadaveric Orthotopic Liver Transplantation

Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients

The PREVENT Resilience Study

Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons

A Phase 1 Study of Intraoperative Administration of CA-008 for the Correction of Hallux Valgus Deformity

A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN)

A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Low Level Light Device as a Primary Therapy for Androgenetic Alopecia

Depakote (Divalproex Sodium) for Children With Temper Dysregulation and Severe Mood Swings

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)

Rescue Emetic Therapy for Children Having Elective Surgery

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

Topiramate in the Treatment of Pathological Gambling

A Study of Paliperidone Palmitate 6-Month Formulation

Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

PPAR-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease

Effect of Tranexamic Acid on Intraoperative Blood Loss in Patients Undergoing Aquablation

Trial of Antimycobacterial Therapy in Sarcoidosis

A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc)

Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

Randomized Trial of NSAID vs Placebo Prior to Ureteral Stent Removal